Compare Sana Biotechnology Inc (SANA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Starbucks Corp — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 127× Sana Biotechnology Inc's market cap, and Starbucks Corp pays a 2.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Starbucks Corp for 190 Days on average.
| SANA | SBUX | |
|---|---|---|
Market Cap | $836.71M | $106.26B |
Volume | 4,507,444 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $108.55 |
52-Week Low | $2.68 | $78.46 |
Typical Hold Time | 23 Days | 190 Days |
Enterprise Value | $749.96M | $125.08B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Starbucks (SBUX) trades at $90.75, down 3.02% today, amid a bearish technical outlook and mixed fundamental performance. The company reported Q2 2026 EPS beat ($0.85 vs. $0.66 expected) but missed in Q4 2025, with revenue growth slowing to 2.8% year-over-year in 2025. Recent news highlights store closures (250 locations) and strategic portfolio reset, while analyst consensus remains positive with a $115.50 price target. Negative shareholder equity and elevated debt levels present financial concerns.
Outlook: Near-term pressure from restructuring and geopolitical risks, but long-term growth potential in high-performing locations and international markets. Risks include execution on store strategy, labor relations, and China exposure. Investment case hinges on successful turnaround and margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
